Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need ...

Rusfertide significantly improves hematocrit control and reduces the mean number of phlebotomies in patients who are phlebotomy-dependent despite standard care. The Food and Drug Administration (FDA) ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

Patients diagnosed with polycythemia vera currently have more specialized treatment options that may lead to improved responses to therapy, an expert said. Dr. Jamile M. Shammo, professor of medicine ...

Findings showed 77% of PV patients treated with rusfertide achieved a clinical response compared with 33% of those who received placebo. Topline data were announced from a phase 3 trial evaluating ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — First-line treatment with ruxolitinib led to “clinically meaningful” positive results versus best ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia ...

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy. The data ...

The current landscape of treatment for polycythemia vera is to reduce the risk of blood clotting and control blood counts. However, future treatments will need to go beyond that and target MPN stem ...

DEAR DR. ROACH: My husband (age 71) received a diagnosis of polycythemia vera a few years ago. I understand this variety of polycythemia isn’t caused by smoking, but we know that smoking does make it ...